Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

[Business Wire] – Bristol-Myers Squibb Company today announced updated results from the Opdivo +Yervoy arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung . . . → Read More: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Similar Articles: Market Update (NYSE:BMY): Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen Stock Update (NYSE:BMY): Roche open to alliances in hunt for cancer drug combinations Market Update (NYSE:BMY): Europe pushes back verdict on Bristol immune system cancer drug